Updated Austrian treatment algorithm in HER2+ metastatic breast cancer

A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios we...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartsch, Rupert, Gampenrieder, Simon Peter, Rinnerthaler, Gabriel, Petru, Edgar, Egle, Daniel, Petzer, Andreas, Balic, Marija, Pluschnig, Ursula, Sliwa, Thamer, Singer, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2022
Materias:
Consensus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813714/
https://www.ncbi.nlm.nih.gov/pubmed/35089396
http://dx.doi.org/10.1007/s00508-021-01987-9
_version_ 1784644921194446848
author Bartsch, Rupert
Gampenrieder, Simon Peter
Rinnerthaler, Gabriel
Petru, Edgar
Egle, Daniel
Petzer, Andreas
Balic, Marija
Pluschnig, Ursula
Sliwa, Thamer
Singer, Christian
author_facet Bartsch, Rupert
Gampenrieder, Simon Peter
Rinnerthaler, Gabriel
Petru, Edgar
Egle, Daniel
Petzer, Andreas
Balic, Marija
Pluschnig, Ursula
Sliwa, Thamer
Singer, Christian
author_sort Bartsch, Rupert
collection PubMed
description A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00508-021-01987-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-8813714
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-88137142022-02-10 Updated Austrian treatment algorithm in HER2+ metastatic breast cancer Bartsch, Rupert Gampenrieder, Simon Peter Rinnerthaler, Gabriel Petru, Edgar Egle, Daniel Petzer, Andreas Balic, Marija Pluschnig, Ursula Sliwa, Thamer Singer, Christian Wien Klin Wochenschr Consensus Report A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00508-021-01987-9) contains supplementary material, which is available to authorized users. Springer Vienna 2022-01-28 2022 /pmc/articles/PMC8813714/ /pubmed/35089396 http://dx.doi.org/10.1007/s00508-021-01987-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Consensus Report
Bartsch, Rupert
Gampenrieder, Simon Peter
Rinnerthaler, Gabriel
Petru, Edgar
Egle, Daniel
Petzer, Andreas
Balic, Marija
Pluschnig, Ursula
Sliwa, Thamer
Singer, Christian
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
title Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
title_full Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
title_fullStr Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
title_full_unstemmed Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
title_short Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
title_sort updated austrian treatment algorithm in her2+ metastatic breast cancer
topic Consensus Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813714/
https://www.ncbi.nlm.nih.gov/pubmed/35089396
http://dx.doi.org/10.1007/s00508-021-01987-9
work_keys_str_mv AT bartschrupert updatedaustriantreatmentalgorithminher2metastaticbreastcancer
AT gampenriedersimonpeter updatedaustriantreatmentalgorithminher2metastaticbreastcancer
AT rinnerthalergabriel updatedaustriantreatmentalgorithminher2metastaticbreastcancer
AT petruedgar updatedaustriantreatmentalgorithminher2metastaticbreastcancer
AT egledaniel updatedaustriantreatmentalgorithminher2metastaticbreastcancer
AT petzerandreas updatedaustriantreatmentalgorithminher2metastaticbreastcancer
AT balicmarija updatedaustriantreatmentalgorithminher2metastaticbreastcancer
AT pluschnigursula updatedaustriantreatmentalgorithminher2metastaticbreastcancer
AT sliwathamer updatedaustriantreatmentalgorithminher2metastaticbreastcancer
AT singerchristian updatedaustriantreatmentalgorithminher2metastaticbreastcancer

Ejemplares similares